NYSE$ACH

Accendra Health Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Owens & Minor's financial performance in Q3 2024 reflected top-line growth driven by patient direct and medical distribution demand and total debt reduction.

Owens & Minor reported a 5% increase in consolidated revenue, reaching $2.7 billion. The company experienced a GAAP net loss of $(13) million, but achieved an adjusted EPS of $0.42. Adjusted EBITDA grew by 5% to $142 million, and total debt was reduced by $198 million.

  • Consolidated revenue increased by 5% year-over-year, reaching $2.7 billion.
  • GAAP Net loss was $(13) million, with adjusted earnings per share at $0.42.
  • Adjusted EBITDA grew by 5% year-over-year to $142 million.
  • Total debt was reduced by $198 million in the third quarter.

Headline financials

Total Revenue

$2.72B

Previous: $2.59B+5.0%
EPS

-$0.17

Previous: $0.44-138.6%
Adjusted Operating Income

$69.4M

No prior period
Adjusted EBITDA

$108M

Previous: $135M-20.1%
Patient Service Equipment CapEx

$27.6M

No prior period
Capital Expenditures

-$148M

Previous: -$140M-5.4%
Free Cash Flow

-$161M

Previous: -$147M-9.5%
Net Income

-$12.8M

Previous: -$6.43M-98.7%
Operating Income

$24.2M

Previous: $23.8M+1.5%
Gross Profit

$560M

Previous: $538M+3.9%
Cash & Equivalents

$45.5M

Previous: $215M-78.9%
Total Assets

$5.08B

Previous: $5.12B-0.8%
Stock-Based Comp

$5.68M

Previous: $5.74M-1.1%

Revenue & EPS history

Owens & Minor · Revenue · Quarterly

$2.72B

Q3 2024+5%vs Q3 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

The company anticipates good sequential growth and cash flow from the third to fourth quarter, positioning them well for 2025. Each segment is expected to benefit from seasonality and recent investments as they finish 2024.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+0.5%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+2.3%

Avg return

30 days after

47%

32 / 68 earnings

Positive

+58.9%

Q2 2019

Best reaction

-37.6%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.7%-18.7%-23.7%
Q4 2025+5.7%+4.8%-21.0%
Q3 2025-4.8%-33.1%-47.9%
Q1 2025-9.6%-6.8%+3.2%
Q4 2024+39.0%+41.4%+24.5%
Q3 2024-11.7%-3.4%+10.3%
Q2 2024-9.4%-9.7%-5.4%
Q1 2024-21.6%-26.1%-28.9%
Q4 2023+2.7%+12.6%+23.1%
Q3 2023+25.0%+19.1%+39.5%
Q2 2023+2.5%+8.4%-6.8%
Q1 2023+31.2%+35.7%+57.4%
Q4 2022-21.3%-13.8%-28.1%
Q3 2022+3.9%+9.2%+19.8%
Q2 2022-10.8%-6.7%-25.8%
Q1 2022+10.3%+4.7%-5.2%
Q4 2021+13.3%+21.0%+21.6%
Q3 2021+23.8%+18.3%+9.5%
Q2 2021-16.8%-16.8%-16.7%
Q1 2021-4.0%-4.7%+19.8%
Q4 2020+27.8%+34.3%+51.3%
Q3 2020+1.3%-2.5%+0.2%
Q2 2020-16.2%-25.0%-2.9%
Q1 2020-6.3%-2.9%+5.6%
Q4 2019-12.0%-30.0%+0.6%
Q3 2019+8.1%+5.9%+16.9%
Q2 2019+58.9%+69.1%+148.1%
Q1 2019+7.4%+7.4%-27.1%
Q4 2018-16.6%-19.1%-45.1%
Q3 2018-37.6%-33.9%-46.3%
Q2 2018-21.7%-24.4%-5.7%
Q1 2018+6.8%+9.4%+8.2%
Q4 2017+4.4%+7.6%+9.3%
Q3 2017-24.0%-21.2%-23.7%
Q2 2017-5.9%-11.9%-13.3%
Q1 2017-4.8%-5.4%-6.3%
Q4 2016-2.6%-2.6%-2.3%
Q3 2016+1.0%+0.6%+5.4%
Q2 2016-0.1%-0.1%-2.3%
Q1 2016-2.2%
Q4 2015+7.9%
Q3 2015+1.1%
Q2 2015+5.1%
Q1 2015+3.8%
Q4 2014-3.3%
Q3 2014-2.1%
Q2 2014-2.7%
Q1 2014-2.4%
Q4 2013+3.8%
Q3 2013-1.5%
Q2 2013-3.5%
Q1 2013+6.9%
Q4 2012-1.1%
Q3 2012-1.0%
Q2 2012-6.0%
Q1 2012-2.5%
Q4 2011-0.1%
Q3 2011-1.5%
Q2 2011+0.3%
Q1 2010-0.2%
Q1 2011+2.1%
Q4 2008+2.5%
Q4 2010+2.5%
Q3 2009-1.4%
Q3 2010-1.4%
Q2 2010+2.4%
Q2 2009+2.4%
Q4 2009+2.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro